X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (63) 63
pulmonary hypertension (59) 59
respiratory system (59) 59
female (54) 54
male (50) 50
middle aged (50) 50
index medicus (40) 40
adult (39) 39
hypertension, pulmonary - physiopathology (31) 31
aged (30) 30
hypertension, pulmonary - drug therapy (30) 30
survival (28) 28
cardiac & cardiovascular systems (27) 27
critical care medicine (24) 24
pulmonary arterial hypertension (23) 23
transplantation (22) 22
abridged index medicus (21) 21
double-blind method (21) 21
follow-up studies (21) 21
adolescent (19) 19
drug therapy (19) 19
hypertension (19) 19
treatment outcome (19) 19
care and treatment (18) 18
research (18) 18
therapy (18) 18
prognosis (17) 17
diagnosis (15) 15
disease (15) 15
hypertension, pulmonary - mortality (15) 15
time factors (15) 15
analysis (14) 14
antihypertensive agents - therapeutic use (14) 14
bosentan (14) 14
medical colleges (14) 14
pulmonary/respiratory (14) 14
risk factors (14) 14
surgery (14) 14
endothelin receptor antagonists (12) 12
lung transplantation (12) 12
registries (12) 12
clinical trials (11) 11
united states - epidemiology (11) 11
usage (11) 11
cardiology and cardiovascular medicine (10) 10
hypertension, pulmonary - diagnosis (10) 10
hypertension, pulmonary - etiology (10) 10
mortality (10) 10
prospective studies (10) 10
ambrisentan (9) 9
double-blind (9) 9
endothelin (9) 9
hemodynamics (9) 9
administration, oral (8) 8
antihypertensive agents - administration & dosage (8) 8
continuous intravenous epoprostenol (8) 8
dose-response relationship, drug (8) 8
drug therapy, combination (8) 8
familial primary pulmonary hypertension (8) 8
heart-failure (8) 8
medicine, general & internal (8) 8
pulmonary arteries (8) 8
retrospective studies (8) 8
sitaxsentan (8) 8
antihypertensive agents - adverse effects (7) 7
combination therapy (7) 7
disease progression (7) 7
dosage and administration (7) 7
exercise test (7) 7
exercise tolerance (7) 7
heart (7) 7
hypertension, pulmonary - epidemiology (7) 7
hypertension, pulmonary - therapy (7) 7
lungs (7) 7
prostacyclin (7) 7
pulmonary (7) 7
registry (7) 7
sulfonamides - therapeutic use (7) 7
tadalafil (7) 7
transplantation of organs, tissues, etc (7) 7
arterial-hypertension (6) 6
brain natriuretic peptide (6) 6
epoprostenol - administration & dosage (6) 6
exercise (6) 6
exercise tolerance - drug effects (6) 6
hemodynamics - physiology (6) 6
hypertension, pulmonary (6) 6
inhaled iloprost (6) 6
isoxazoles - therapeutic use (6) 6
medical research (6) 6
medicine, experimental (6) 6
patient outcomes (6) 6
patients (6) 6
respiratory agents (6) 6
reveal (6) 6
survival rate (6) 6
survival rate - trends (6) 6
thiophenes - therapeutic use (6) 6
walking - physiology (6) 6
young adult (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Chest, ISSN 0012-3692, 09/2011, Volume 140, Issue 3, pp. 829 - 830
Journal Article
Chest, ISSN 0012-3692, 11/2018, Volume 154, Issue 5, pp. 1262 - 1264
Journal Article
Chest, ISSN 0012-3692, 11/2018, Volume 154, Issue 5, pp. 1262 - 1264
Journal Article
Chest, ISSN 0012-3692, 11/2018, Volume 154, Issue 5, pp. 1262 - 1264
Journal Article
Respiratory research, ISSN 1465-993X, 09/2019, Volume 20, Issue 1, pp. 208 - 10
Initial combination therapy with ambrisentan and tadalafil reduced the risk of clinical failure events for treatment-naïve participants with pulmonary arterial... 
DOUBLE-BLIND | SELEXIPAG | Combination therapy | RESPIRATORY SYSTEM | Research-clinical | Pulmonary hypertension | Hypertension | Confidence intervals | Therapy | Clinical trials | Risk analysis | Patients | Subgroups | Research
Journal Article
Chest, ISSN 0012-3692, 08/2019, Volume 156, Issue 2, pp. 323 - 337
Pulmonary arterial hypertension is a progressive, fatal disease. Published treatment guidelines recommend treatment escalation on the basis of regular patient... 
risk score calculator | registry | REVEAL | pulmonary arterial hypertension | ESC/ERS-derived risk assessment
Journal Article
Chest, ISSN 0012-3692, 07/2018, Volume 154, Issue 1, pp. 126 - 135
Background: Plasma brain natriuretic peptide (BNP) level is a prognostic biomarker in pulmonary arterial hypertension (PAH). Its impact on long-term overall... 
brain natriuretic peptide | mortality | pulmonary arterial hypertension | biomarkers | survival | DIAGNOSIS | RESPIRATORY SYSTEM | EPIDEMIOLOGY | CRITICAL CARE MEDICINE | Brain natriuretic peptide | Treatment outcome | Prognosis | Health aspects | Analysis | Pulmonary hypertension
Journal Article
Chest, ISSN 0012-3692, 07/2018, Volume 154, Issue 1, pp. 126 - 135
Plasma brain natriuretic peptide (BNP) level is a prognostic biomarker in pulmonary arterial hypertension (PAH). Its impact on long-term overall survival (OS)... 
brain natriuretic peptide | mortality | pulmonary arterial hypertension | biomarkers | survival
Journal Article
Journal Article
Methodist DeBakey Cardiovascular Journal, ISSN 1947-6094, 2016, Volume 12, Issue 4 Suppl, pp. 10 - 13
Pulmonary hypertension (PH) is a complication and marker of disease severity in many parenchymal lung diseases. It also is a frequent complication of portal... 
parenchymal lung disease | pulmonary hypertension | Supplement | end-stage renal disease | COPD
Journal Article
Journal of Heart and Lung Transplantation, ISSN 1053-2498, 12/2018, Volume 37, Issue 12, pp. 1410 - 1417
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2015, Volume 373, Issue 9, pp. 834 - 844
Patients with previously untreated pulmonary arterial hypertension who were randomly assigned to combination therapy with ambrisentan and tadalafil had a... 
INHALED ILOPROST | SURVIVAL | TRIAL | DIAGNOSIS | MEDICINE, GENERAL & INTERNAL | EPOPROSTENOL | COMBINATION THERAPY | HEART-FAILURE | DOUBLE-BLIND | BOSENTAN | Hypertension, Pulmonary - mortality | Double-Blind Method | Humans | Middle Aged | Risk Factors | Kaplan-Meier Estimate | Hypertension, Pulmonary - physiopathology | Male | Hospitalization | Disease Progression | Tadalafil | Phenylpropionates - therapeutic use | Peptide Fragments - blood | Adult | Female | Phenylpropionates - adverse effects | Aged | Hypertension, Pulmonary - drug therapy | Drug Therapy, Combination | Carbolines - therapeutic use | Carbolines - adverse effects | Natriuretic Peptide, Brain - blood | Pyridazines - adverse effects | Pyridazines - therapeutic use | Symptomatology | Care and treatment | Usage | Analysis | Clinical trials | Dosage and administration | Pulmonary hypertension | Ambrisentan | Hypertension | Edema | Brain natriuretic peptide | Headache | Functional morphology | Pulmonary arteries | Lung diseases | Drug therapy | Patients | Clinical outcomes | Drug side effects | Assaigs clínics de medicaments | Efectes secundaris dels medicaments | Hipertensió pulmonar | Drug testing | Life Sciences | Human health and pathology | Kardiologi | Clinical Medicine | Cardiac and Cardiovascular Systems | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.